Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Ying Wang, MD
CONTACT
Lead
Institute of Hematology & Blood Diseases Hospital, China
With
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases.Study intervention consists of a single infusion of universal allogeneic CART-cells administered intravenously after a lymphodepleting therapy regimen of cyclophosphamide.Interim analysis will be performed when participants finish the visit at 12 and 24 weeks after CAR T-cell infusion.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted